Search results for "Inde"

showing 10 items of 7365 documents

Preference for attractiveness and thinness in a partner: Influence of internalization of the thin ideal and shape/weight dissatisfaction in heterosex…

2009

This study assesses whether characteristics of one's own body image influences preferences of attractiveness in a partner. The role of gender and sexual orientation is also considered. Heterosexual women (n=67), lesbian women (n=73), heterosexual men (n=61) and gay men (n=82) participated in an internet survey assessing attitudes towards the body and preferences of attractiveness in a partner. Men in particular were found to prefer attractive partners, regardless of sexual orientation. Weight/shape dissatisfaction was found to be a negative predictor for heterosexual men and women. For gay men, preferences were better explained by internalization and weight/shape dissatisfaction. No such as…

AdultMaleAttractivenessAdolescentSocial ValuesSocial Psychologymedia_common.quotation_subjecteducationPersonal SatisfactionSocial value orientationsChoice BehaviorBody Mass IndexBeautyYoung AdultThinnessThe Thin IdealBody ImageBody SizeHumansHomosexualityHomosexuality MaleHeterosexualityInternal-External ControlGeneral PsychologyApplied Psychologymedia_commonBody WeightHomosexuality FemaleHealth SurveysPreferenceSexual PartnersSexual orientationFemaleLesbianPsychologyBody mass indexSocial psychologyBody Image
researchProduct

A Highly Decreased Binding of Cyclic Adenosine Monophosphate to Protein Kinase A in Erythrocyte Membranes is Specific for Active Psoriasis

2002

A cyclic adenosine monophosphate binding abnormality in psoriatic erythrocytes that could be corrected by retinoid treatment has been reported. It was tested whether this binding abnormality is specific for psoriasis and the effects of treatment were compared with etretinate, cyclosporine A, or anthralin on 2-(3)H-8-N(3)-cyclic adenosine monophosphate binding to the regulatory subunit of protein kinase A in erythrocyte membranes. One hundred and fifteen individuals were evaluated, including: (i) 34 healthy persons; (ii) 15 patients with nonatopic inflammatory skin diseases (eczema, erythroderma, tinea, Grover's disease, erysipelas, urticaria); (iii) eight with other dermatoses mediated by i…

AdultMaleAzidesmedicine.medical_specialtyAdolescentmedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsErythrodermaEtretinateDermatologySeverity of Illness IndexBiochemistryRetinoidschemistry.chemical_compoundPsoriasis Area and Severity IndexKeratolytic AgentsPsoriasis Area and Severity IndexPsoriasisInternal medicineCyclic AMPmedicineHumansPsoriasisCyclic adenosine monophosphateRetinoidMolecular BiologydermatitisAgedErythema nodosumbusiness.industryErythrocyte MembraneAffinity LabelsCell BiologyAtopic dermatitisAnthralinMiddle Agedmedicine.diseaseCyclic AMP-Dependent Protein KinasesEndocrinologychemistryEtretinateCyclosporineFemaleDermatologic Agentsbusinesscyclosporine AProtein Bindingmedicine.drugJournal of Investigative Dermatology
researchProduct

Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis

2021

Background: Knowledge regarding the impact of body composition measures on pharmacokinetics of antipsychotics is limited. Aims: Our aim was to investigate the impact of body weight and body mass index on clozapine pharmacokinetics using a therapeutic drug monitoring database. Methods: A large therapeutic drug monitoring dataset of clozapine plasma concentrations considering three patient subgroups was analysed: a control group (CLZ0, 20–30 kg/m2, n=266), a group with high body mass index (CLZhigh, body mass index ⩾30 kg/m2, n=162) and with low body mass index values (CLZlow, body mass index <20 kg/m2, n=27). Comparisons of plasma and dose-adjusted plasma concentrations (C/D) of clozapine…

AdultMaleBiological AvailabilityPharmacologyBody weightBody Mass IndexYoung Adult03 medical and health sciencesSex Factors0302 clinical medicinePharmacokineticsmedicineHumansTissue DistributionPharmacology (medical)ObesityClozapineClozapineAgedRetrospective StudiesA determinantAged 80 and overPharmacologymedicine.diagnostic_testbusiness.industryBody WeightMiddle Agedmedicine.diseaseObesity030227 psychiatryPsychiatry and Mental healthAdipose TissueLiverTherapeutic drug monitoringPlasma concentrationFemaleDrug MonitoringbusinessBody mass index030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugJournal of Psychopharmacology
researchProduct

Contribution of genetic and environmental factors to variation in body compartments--a twin study in adults.

2004

This study aimed at analyzing the contribution of genetic and environmental factors on phenotypic variation of various traits of body composition. Subjects were 30 same-sexed pairs of twins including 20 monozygous (MZ) and 10 dizygous (DZ) pairs, aged 19-62 years. Zygosity was determined by DNA typing and morphological diagnosis. Body composition parameters (fat mass FM, lean body mass LBM, body cell mass BCM, extracellular mass ECM, total body water TBW, extracellular water ECW, and intracellular water ICW) were estimated by tetrapolar bioelectrical impedance analysis. Potential environmental factors influencing body composition (number of children, sporting activity and smoking behaviour)…

AdultMaleBody waterHealth BehaviorStatistics as TopicBiologySocial EnvironmentBody Mass IndexAnimal scienceQuantitative Trait HeritableGermanyTwins DizygoticHumansLife StyleEcology Evolution Behavior and SystematicsModels StatisticalBody WeightGeneral MedicineTwins MonozygoticStepwise regressionHeritabilityMiddle AgedTwin studyZygosityPhenotypeSocioeconomic FactorsAnthropologyLean body massBody CompositionAnimal Science and ZoologyFemaleBody mass indexBioelectrical impedance analysisDemographyAnthropologischer Anzeiger; Bericht uber die biologisch-anthropologische Literatur
researchProduct

The use of esmolol in whole-body hyperthermia: Cardiovascular effects

1997

Whole-body hyperthermia (WBH) is a well-described investigational adjunct to systemic chemotherapy for the treatment of advanced malignancies. The hemodynamic consequences of this physiologic state may include tachycardia, which can produce acute myocardial ischemia in patients with coronary artery disease. Ischemic heart disease is currently considered a contraindication to WBH. We chose to investigate the consequences of using a new beta 1-adrenergic antagonist, esmolol, to attempt to control the tachycardia associated with WBH. After institutional approval and patient consent, nine consecutive patients with normal cardiac function presenting for WBH with carboplatin infusion were studied…

AdultMaleCancer ResearchMean arterial pressureCardiac outputHeart diseasePhysiologySinus tachycardiaAdrenergic beta-AntagonistsCardiac indexAntineoplastic AgentsCoronary DiseaseCarboplatinPropanolaminesHeart RateNeoplasmsTachycardiaPhysiology (medical)Heart rateHumansMedicineInfusions Intravenousbusiness.industryContraindicationsHemodynamicsHyperthermia InducedMiddle Agedmedicine.diseaseEsmololCombined Modality TherapyAnesthesiaHeart failureFemaleSafetymedicine.symptombusinessmedicine.drugInternational Journal of Hyperthermia
researchProduct

[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation

2003

The nucleoside 5-fluoro-2-deoxyuridine is a pyrimidine analogue accumulating in proliferative cells. We prospectively evaluated biodistribution of the PET tracer [(18)F]5-fluoro-2-deoxyuridine (FdUrd), its value for imaging malignant tumors, and its correlation to both [(18)F]2-fluoro-2-deoxyglucose (FDG)-PET findings and histological proliferation indices. In 11 previously untreated patients (5 lung carcinoma; 3 soft tissue sarcoma; 2 gastrointestinal carcinoma; 1 non-Hodgkin lymphoma [NHL]), mean doses of 290 MBq FdUrd and 390 MBq FDG were administered intravenously on subsequent days. Static PET scans were initiated 50-70 min after administration and the mean standardized uptake values (…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsProliferation indexUrinary BladderKidneyBone and BonesPyrimidine analogueFluorodeoxyglucose F18NeoplasmsmedicineCarcinomaHumansTissue DistributionRadiology Nuclear Medicine and imagingProspective StudiesAgedGastrointestinal NeoplasmsNeoplasm StagingPharmacologymedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinSoft tissue sarcomaKidney metabolismSarcomaGeneral MedicineMiddle Agedmedicine.diseaseLymphomaKi-67 AntigenLiverOncologyPositron emission tomographyFemaleSarcomaRadiopharmaceuticalsbusinessNuclear medicineCell DivisionTomography Emission-Computed
researchProduct

Clinical relevance of thymidylate syntetase expression in the signet ring cell histotype component of colorectal carcinoma

2004

Thymidylate Synthase (TS) is the key enzyme for DNA synthesis pathways and is inhibited by 5-fluorouracil (5FU). The aim of this work was to study TS expression and the proliferation rate in the different histological types of colorectal carcinoma (CRC). 50 patients with CRC were included in this study and evaluated immunohistochemically using the monoclonal antibodies, TS106 and Ki67. 20 tumours were of the intestinal type, 15 cases were signet ring cell carcinoma (SRCCs) and 15 cases were "mixed-type", with at least two different histological components. Intestinal and mucinous histotypes were positive for TS and Ki67, while "signet ring cell" samples were negative or showed only weak and…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyProliferation indexColorectal cancerSettore MED/08 - Anatomia PatologicaThymidylate synthase expressionThymidylate synthaseSignet ring cell carcinomaSignet ring cell carcinomaCarcinomamedicineHumansThymidylate synthase expression; Signet ring cell carcinoma; Colorectal carcinoma; ImmunohistochemistryAgedbiologySignet ring cellThymidylate SynthaseMiddle AgedCell cyclemedicine.diseaseImmunohistochemistrydigestive system diseasesNeoplasm ProteinsColorectal carcinomaKi-67 AntigenOncologybiology.proteinCancer researchSettore BIO/14 - FarmacologiaImmunohistochemistryFemaleColorectal NeoplasmsCarcinoma Signet Ring Cell
researchProduct

Cyclosporin- and nifedipine-induced gingival overgrowth in renal transplant patients: correlations with periodontal and pharmacological parameters, a…

1996

The factors associated with cyclosporin A (CsA)- and nifedipine (Nif)-induced gingival overgrowth were investigated in 113 renal transplant recipients receiving CsA alone (Group 1) [n = 61], CsA and Nif (Group 2) [n = 28], or azathioprine (Aza) (Control Group) [n = 24]. Periodontal and pharmacological parameters were assessed for each patient. The patients with a gingival overgrowth index (GOI) score1 were considered responders (R); those with a score/= 1 were non-responders (NR). Gingival overgrowth occurred in 33.7% of the patients in Groups 1 and 2; 60% of the responders were receiving CsA+Nif. In R, no relationship was found between the GOI and the periodontal and pharmacological parame…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentNifedipineAzathioprineGastroenterologyPathology and Forensic MedicinePathogenesisNifedipineHLA AntigensInternal medicineCyclosporin aAzathioprinePrevalencemedicineHumansPeriodontal PocketDental CalculusChildSalivaKidney transplantationKidneyHLA-A AntigensGingival Overgrowthbusiness.industryDental Plaque IndexMiddle AgedCalcium Channel Blockersmedicine.diseaseGingivitisKidney TransplantationTransplantationEndocrinologymedicine.anatomical_structureOtorhinolaryngologyToxicityCyclosporineIrritantsPeriodonticsFemaleDisease SusceptibilityPeriodontal IndexOral SurgerybusinessImmunosuppressive Agentsmedicine.drugJournal of Oral Pathology and Medicine
researchProduct

Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph consortium

2008

Nutritional status is known to alter immune function, a suspected risk factor for non-Hodgkin lymphoma (NHL). To investigate whether long-term over, or under, nutrition is associated with NHL, self-reported anthropometric data on weight and height from over 10,000 cases of NHL and 16,000 controls were pooled across 18 case-control studies identified through the International Lymphoma Epidemiology Consortium. Study-specific odds ratios (OR) were estimated using logistic regression and combined using a random-effects model. Severe obesity, defined as BMI of 40 kg m-2 or more, was not associated with NHL overall (pooled OR = 1.00, 95% confidence interval (CI) 0.70-1.41) or the majority of NHL …

AdultMaleCancer Researchmedicine.medical_specialtyInternational CooperationOverweightRisk AssessmentArticleBody Mass IndexRisk FactorsInternal medicinehemic and lymphatic diseasesEpidemiologyOdds RatiomedicineHumansObesityRisk factorAgedbusiness.industryLymphoma Non-HodgkinBody WeightNon-Hodgkin lymphoma obesity pooled analysis InterLymph consortiumOdds ratioMiddle Agedmedicine.diseaseObesityBody HeightConfidence intervalSurgeryOncologyFemaleLymphoma Large B-Cell Diffusemedicine.symptomUnderweightbusinessBody mass index
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct